- Conditions
- Anaplastic Large-Cell Lymphoma
- Interventions
- SGN-30 (anti-CD30 mAb)
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2233–2256
of 7,879
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type I Diabetes Mellitus Without Complication, Eating Disorder
- Interventions
- Not listed
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 14 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
- Interventions
- ACE-232 tablets
- Drug
- Lead sponsor
- Acerand Therapeutics (Hong Kong) Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- La Jolla, California • Tampa, Florida • Baltimore, Maryland + 5 more
- Conditions
- Heart Failure, ADHF, Chronic Heart Failure, CHF
- Interventions
- Cenderitide, Placebo
- Drug · Other
- Lead sponsor
- Nile Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 5
- States / cities
- Tustin, California • Jacksonville, Florida • Lenexa, Kansas + 2 more
- Conditions
- Coronary Artery Disease
- Interventions
- ABT NG DES 48 EECSS
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 13 more
- Conditions
- Severe Orthopedic Trauma
- Interventions
- Trauma Collaborative Care Plus Treatment as Usual
- Behavioral
- Lead sponsor
- Major Extremity Trauma Research Consortium
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Tampa, Florida • Indianapolis, Indiana + 9 more
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Zalcitabine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 2,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1995
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 34 more
- Conditions
- Candidiasis, Mycoses, HIV Infections
- Interventions
- Clotrimazole, Fluconazole
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 25
- States / cities
- Palo Alto, California • San Diego, California • San Francisco, California + 18 more
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Large-cell Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Marginal Zone B-cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-cell Lymphoma, Prolymphocytic Leukemia, Bone Marrow Failure Syndromes, Myeloproliferative Neoplasms/Myelofibrosis, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Leukemia or MDS in Aplasia, Relapsed T-Cell Lymphoma, Relapsed Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Fludarabine, Cyclophosphamide, MMF, Sirolimus, TBI, Umbilical cord blood cell infusion, ATG
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Acne
- Interventions
- Acne mRNA vaccine, Placebo
- Biological · Other
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 79
- States / cities
- Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more
- Conditions
- COVID-19
- Interventions
- BRII-196, BRII-198, Placebo, Remdesivir
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 76
- States / cities
- Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 86
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more
- Conditions
- Breast Cancer, Depression, Fatigue, Sleep Disorders
- Interventions
- Metformin, Placebo
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years to 74 Years · Female only
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 252
- States / cities
- Anaheim, California • Antioch, California • Baldwin Park, California + 185 more
- Conditions
- Hyperkalemia
- Interventions
- Patiromer Powder for Oral Suspension [Veltassa], Placebo
- Drug
- Lead sponsor
- Comprehensive Research Associates
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 19
- States / cities
- Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more
- Conditions
- Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- Interventions
- TX000045- Dose A, TX000045- Dose B, Placebo
- Drug
- Lead sponsor
- Tectonic Therapeutic
- Industry
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
- Conditions
- Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
- Interventions
- Bevacizumab, Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim, Placebo
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 201
- States / cities
- Phoenix, Arizona • Burbank, California • Concord, California + 138 more
- Conditions
- Tobacco Use
- Interventions
- Nicotine Replacement Therapy, Counseling
- Drug · Behavioral
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Thoracoabdominal Aneurysm
- Interventions
- GORE Excluder Thoracoabdominal Branch Endoprosthesis
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 19 Years and older
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 48
- States / cities
- Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more
- Conditions
- Atrial Fibrillation
- Interventions
- Patients with Atrial Fibrillation (AF)
- Other
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10,179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 165 more
- Conditions
- Rheumatoid and Osteoarthritis
- Interventions
- Weight control and physical activity promotion
- Behavioral
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- GT005
- Drug
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more
- Conditions
- Uncontrolled Hypertension
- Interventions
- RPD, Active hypertension medical therapy
- Device · Drug
- Lead sponsor
- Verve Medical, Inc
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Surprise, Arizona • Los Angeles, California + 6 more
- Conditions
- Anaemia
- Interventions
- Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 3,872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 161
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more